我要投票 马应龙八宝Mabo's在眼霜行业中的票数:614
· 外 推 电 报 ·
2025-08-20 08:47:44 星期三

【马应龙八宝Mabo's是哪个国家的品牌?】

马应龙八宝Mabo's是什么牌子?「马应龙八宝Mabo's」是 马应龙药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北武汉,由创始人陈平经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力马应龙八宝Mabo's品牌出海!将品牌入驻外推网,定制马应龙八宝Mabo's品牌推广信息,可以显著提高马应龙八宝Mabo's产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

马应龙是一家经国家商务部认定的中华老字号企业,创始于公元1582年。经过多年持续快速健康发展,马应龙已经成为一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的专业化多功能国际化的医药类上市公司。

公司与北京大学药学院、中国药科大学等多家科研机构建立了长期的战略合作关系。经国家人事部核准公司与北京大学共同组建了博士后工作站。2009年,马应龙药业集团股份有限公司技术中心被国家发改委、科技部等五部委认定为国家级企业技术中心,马应龙创新药物研发团队被湖北省委组织部认定为首批“湖北省重点产业创新团队”。

马应龙及旗下子公司分别通过了国家药监局GMP、GSP质量管理规范体系认证,获得国际权威机构SGS颁发的环境管理体系ISO14000和职业安全与健康管理体系OHSAS18000的认证,在医药行业内率先实现了“三认证”。在世界品牌实验室、世界经理人周刊联合评估的2009年“中国最具价值品牌500强”排行榜中,马应龙名列第213位,品牌价值达到了40.01亿元。2006年马应龙荣获国家工商总局认定的“驰名保护”。2009年,马应龙被中国非处方药物协会评选为“中国非处方药品牌企业十五强”

公司股票于2004年在上海证券交易所上市,由此获得了持续融资的通道和规范营运的平台。2007年,公司股票被上海证券交易所、中国证券指数公司选定为中国上市公司治理指数样本股,标志着公司治理水平获得社会公众、证券机构及专家的高度认可。

传承四百多年的历史文化,公司逐步形成了具有马应龙特色的企业文化体系。公司秉承“为顾客创造健康,为股东创造财富,为员工创造机会,为社会创造效益”的经营宗旨,倡导“以真修心,以勤修为”的哲学观,倡导“稳健经营、协调发展”的经营观,倡导“资源增值”的价值观,弘扬“龙马精神”的企业精神。马应龙将以实现中药现代化为己任,在品牌经营战略的指引下与时俱进,继往开来。


英文翻译:Ma Yinglong is a Chinese time-honored enterprise recognized by the Ministry of Commerce. It was founded in 1582 ad. After years of sustained, rapid and healthy development, Ma Yinglong has become a professional, multi-functional and international pharmaceutical listed company involved in drug manufacturing, drug research and development, drug wholesale and retail, chain hospitals and other fields. The company has established a long-term strategic cooperation relationship with many scientific research institutions, such as the school of pharmacy of Peking University and China Pharmaceutical University. With the approval of the Ministry of personnel of the people's Republic of China, the company and Peking University jointly set up a postdoctoral workstation. In 2009, the technology center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by five ministries and commissions including the national development and Reform Commission and the Ministry of science and technology, and the R & D team of Ma Yinglong innovative drugs was recognized as the first batch of "Hubei key industry innovation team" by the Organization Department of Hubei Provincial Committee. Ma Yinglong and its subsidiaries have respectively passed the GMP and GSP quality management standard system certification issued by the State Food and drug administration, obtained the certification of ISO14000 environmental management system and OHSAS18000 occupational safety and health management system issued by the international authoritative agency SGS, and took the lead in realizing the "three certifications" in the pharmaceutical industry. In the 2009 "top 500 most valuable brands in China" list jointly evaluated by world brand laboratory and World Manager weekly, Ma Yinglong ranked 213, with the brand value reaching 4.001 billion yuan. In 2006, Ma Yinglong was awarded "famous protection" by the State Administration for Industry and commerce. In 2009, Ma Yinglong was listed on Shanghai Stock Exchange in 2004 as one of the "top 15 Chinese over-the-counter drug brand enterprises" by China over-the-counter drug association, thus obtaining a channel for continuous financing and a platform for standardized operation. In 2007, the company's stock was selected as the sample stock of China's listed corporate governance index by Shanghai Stock Exchange and China Securities Index company, marking that the level of corporate governance was highly recognized by the public, securities institutions and experts. Inheriting more than 400 years of history and culture, the company has gradually formed a corporate culture system with Ma Yinglong's characteristics. The company adheres to the business tenet of "creating health for customers, creating wealth for shareholders, creating opportunities for employees and creating benefits for the society", advocates the philosophy of "cultivating the heart with sincerity, cultivating the mind with diligence", advocates the business concept of "stable operation and coordinated development", advocates the value concept of "resource added value", and promotes the enterprise spirit of "Longma spirit". Ma Yinglong will take the modernization of traditional Chinese medicine as his duty, keep pace with the times and carry forward the past and open up the future under the guidance of brand management strategy.

本文链接: https://www.waitui.com/brand/92904fecd.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

啤酒企业探索“啤酒+饮品”战略布局

据统计,截至8月19日,A股7家啤酒上市公司中,重庆啤酒股份有限公司、北京燕京啤酒股份有限公司、福建省燕京惠泉啤酒股份有限公司均已披露了2025年半年度报告。另外,广州珠江啤酒股份有限公司、西藏发展股份有限公司、兰州黄河企业股份有限公司三家啤酒上市公司已发布半年度业绩预告。在上述啤酒上市公司发布的半年度业绩预告或半年报中,大多提及竞争加剧是行业面临的共同挑战。与此同时,探索多元化发展路径成为行业共识,构建“啤酒+饮品”版图成为部分公司战略发展的重心。(证券日报)

48分钟前

中金:具身机器人行业进入迅速发展阶段,建议关注国内线缆厂配套成长机遇

36氪获悉,中金研报称,近年来,具身机器人行业进入迅速发展阶段,宇树等头部主机厂实现小批量出货、开始意识到线缆的机械性能和使用寿命对于机器人本体的重要性;我们认为具身机器人线缆行业进入壁垒高、市场潜力足,有望随头部主机厂同步放量,建议关注国内线缆厂配套成长机遇。

48分钟前

乘股市回暖东风,含权类理财产品销售升温

在政策与市场的双轮驱动下,不少含权类理财产品近期表现亮眼。有银行客户经理表示,部分业绩表现良好的含权类理财产品出现了资金持续流入的情况。含权类理财产品销售热度升温的背后,离不开银行理财公司的大力布局。采访多家国有大行、股份行、城商行理财公司内部人士发现,加大布局含权类理财产品已成为行业共识。有银行理财公司人士表示,在“资产荒”背景下,含权类理财产品有望成为银行理财公司提升产品规模的重要发力点。(中证网)

48分钟前

华泰证券:重视稀土战略地位,看好价格上行

36氪获悉,华泰证券研报称,重视稀土战略地位,看好价格上行。预期2025—2026年稀土价格中枢有望持续上行。此外,在“逆全球化”背景下,稀土的战略意义愈发凸显。7月启动的金属镨钕竞拍表现活跃,市场看涨情绪浓烈。在稀土价格中枢有望上行的背景下,预期相关公司业绩将持续改善。

48分钟前

绩优产品限购 配置菜单更新,基金公司营销“画风”生变

近期市场行情火热,不少绩优基金却开启了“限购”模式。这既是避免基金规模快速扩张,从而摊薄现有基金持有人收益的需要,也是基金公司从规模导向向投资者回报导向转型的体现。梳理发现,近期限购的绩优基金多聚焦于创新药、科技、军工等今年以来的热门赛道,这些赛道交易普遍较为拥挤。与此同时,不少基金公司也在挖掘一些其他细分赛道的基金或是“固收+”、FOF等产品,为投资者均衡配置提供可选“菜单”。(中证网)

48分钟前

本页详细列出关于马应龙八宝Mabo's的品牌信息,含品牌所属公司介绍,马应龙八宝Mabo's所处行业的品牌地位及优势。
咨询